Alder Biopharmaceuticals, Inc. (ALDR) EPS Estimated At $-1.26

April 19, 2018 - By Marie Mckinney

Analysts expect Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) to report $-1.26 EPS on April, 26.They anticipate $0.73 EPS change or 36.68 % from last quarter’s $-1.99 EPS. After having $-0.80 EPS previously, Alder Biopharmaceuticals, Inc.’s analysts see 57.50 % EPS growth. The stock decreased 0.34% or $0.05 during the last trading session, reaching $14.5. About 1.11 million shares traded. Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) has declined 46.26% since April 19, 2017 and is downtrending. It has underperformed by 57.81% the S&P500.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Coverage

Among 4 analysts covering Alder BioPharmaceuticals (NASDAQ:ALDR), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Alder BioPharmaceuticals had 8 analyst reports since October 27, 2017 according to SRatingsIntel. As per Friday, January 12, the company rating was maintained by Canaccord Genuity. Needham maintained the shares of ALDR in report on Wednesday, November 8 with “Buy” rating. The stock of Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) earned “Buy” rating by Canaccord Genuity on Thursday, February 8. The stock has “Buy” rating by RBC Capital Markets on Monday, January 8. BMO Capital Markets maintained Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) rating on Monday, January 8. BMO Capital Markets has “Buy” rating and $26.0 target. The firm has “Buy” rating given on Tuesday, January 30 by Canaccord Genuity. The firm has “Buy” rating by BMO Capital Markets given on Tuesday, January 2.

Alder BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes therapeutic antibodies in the United States, Australia, and Ireland. The company has market cap of $983.75 million. The company's lead product candidate includes ALD403, an antibody, which is in Phase II clinical trial to target calcitonin gene-related peptide for the prevention of migraine. It currently has negative earnings. It also develops ALD1910, a genetically engineered monoclonal antibody that is in preclinical study for the treatment of migraine; and Clazakizumab, an antibody, which has been completed Phase IIb clinical trial that inhibits the pro-inflammatory cytokine interleukin-6 for the treatment of rheumatoid and psoriatic arthritis.

Alder Biopharmaceuticals, Inc. (NASDAQ:ALDR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.